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Background: Pentavalent antimonials (Sb5) and miltefosine are the first-line drugs for treating cutaneous
leishmaniasis in Colombia; however, toxicity and treatment duration negatively impact compliance and cost,
justifying an active search for better therapeutic options. We compared the efficacy and safety of thermotherapy
and Meglumine antimoniate for the treatment of cutaneous leishmaniasis in Colombia.
Method: An open randomized Phase III clinical trial was performed in five military health centres. located in
northwestern, central and southern Colombia. Volunteers with parasitological positive diagnosis (Giemsa-stained
smears) of cutaneous leishmaniasis were included. A single thermotherapy session involving the application of 50°C
at the center and active edge of each lesion. Meglumine antimoniate was administered intramuscularly at a dose of
20 mg Sb5/kg weight/day for 20 days.
Results: Both groups were comparable. The efficacy of thermotherapy was 64% (86/134 patients) by protocol and
58% (86/149) by intention-to-treat. For the Meglumine antimoniate group, efficacy by protocol was 85% (103/121
patients) and 72% (103/143) by intention-to-treat, The efficacy between the treatments was statistically
significant (p 0.01 and <0.001) for analysis by intention to treat and by protocol, respectively. There was no
difference between the therapeutic response with either treatment regardless of the Leishmania species
responsible for infection. The side effects of Meglumine antimoniate included myalgia, arthralgia, headache
and fever. Regarding thermotherapy, the only side effect was pain at the lesion area four days after the
initiation of treatment.
Conclusion: Although the efficacy rate of Meglumine antimoniate was greater than that of thermotherapy
for the treatment of cutaneous leishmaniasis, the side effects were also greater. Those factors, added to the
increased costs, the treatment adherence problems and the progressive lack of therapeutic response, make
us consider thermotherapy as a first line treatment for cutaneous leishmaniasis. Registered ClinicalTrials.gov
NCT00471705
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Leishmaniasis is a group of diseases caused by parasites
from the Leishmania genus. It is transmitted by female
insects from the Lutzomyia genus in America and
Phlebotomus in the Old World, affecting humans and
domestic and wild mammals [1,2]. It is endemic in more
than 98 countries. There are 2 million new cases per year,
of which 1.5 million present in the cutaneous form [3].* Correspondence: idvelez@pecet-colombia.org
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in any medium, provided the original work isIn Colombia, there has been a reappearance of
leishmaniasis. During the years of 2005–2008, 61,120
new cases were diagnosed. Among these cases, 34,262
(56.1%) occurred in National Army soldiers Statistical
data (Dirección de Sanidad del Ejército (DISAN)).
Since the 1940s, the pentavalent antimonials (Sb5)
(Meglumine antimoniate and sodium stibogluconate) have
been considered first line medications for the treatment of
leishmaniasis. In Colombia, health authorities recommend a
20 mg Sb5/kg/day dose for 20 days to treat cutaneous leish-
maniasis and 28 days of therapy to treat mucosal
leishmaniasis (ML) and visceral leishmaniasis (VL) [4].s an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
properly cited.
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(approximately $200 per patient), cardiotoxic (P wave
prolongation, inverted T waves, ST elevation and QT
prolongation), hepatotoxic (liver enzymes elevation),
nephrotoxic (BUN and creatinine elevation) and can also
cause pancreatitis, leukopenia, thrombocytopenia, arth-
ralgia and myalgia.
These complications, in combination with the parenteral
route and the duration of treatment, cause adherence pro-
blems. Antimonials are contraindicated during pregnancy
and lactation, in very young children, in patients with hyper-
sensitivity to the drug and in patients suffering from chronic
conditions. Some reports have shown a decrease in the
sensitivity of Leishmania parasites to antimonials [3-
13]. In the Old World leishmaniasis caused by L. (L) tro-
pica, the parasite resistance is the main problem for the use
of antimony [14,15]. Therefore, all of the factors mentioned
above reinforce the need for alternative therapies.
Several oral medications have been tested for the treat-
ment of CL, such as dapsone [16], ketoconazol [17,18],
mefloquine [19], allopurinol [20], miltefosine [21-25] and
others [4], none of which are completely effective. Com-
parisons of the efficacy of different drugs are compli-
cated by the different protocols used in each study.
According to a recent meta-analysis of clinical trials for
CL, this lack of standardization of methodologies makes
it impossible to obtain conclusive information [4,26,27].
Some studies have shown that it is possible to induce
healing of lesions by treatment with local heat [28-30].
Ethnomedical studies have shown that, in rural communi-
ties of South America and Africa, the empiric application of
caustic materials (powder, hot brown sugar, silver nitrate,
oil, battery) or the cauterization of the lesions with hot
metal objects (spoons, knifes) is very common [31-33]. Cur-
rently, we employ the local application of an instrument,
maintained at 50°C, called ThermomedW. This equipment
was used in this study [34].
In addition to the benefits of local treatment, the cost
of thermotherapy is significantly lower than the pentava-
lent antimony. The antimony cost is approximately USD
37.2, which must be added on to the patients disability,
medical test before, during and after treatment, and in
cases where it is needed, the electrocardiogram. According
to calculations by dermatologist of the study, the total cost
of local heat therapy, does not exceed USD 20 [3].
The objective of this study was to evaluate the efficacy
and safety of Thermotherspy compared with Meglumine
antimoniate for the treatment of Cutaneous Leishmnaniosis
in Colombia.
Materials and methods
Study design We conducted an open randomized,
phase III clinical trial to compare the differences inefficacy and safety between thermotherapy and Meglu-
mine antimoniate.
Population and site of the study The study was con-
ducted between June 2006 and April 2008. The subjects
were adult males enlisted in the Colombian Army. The
study took place in five military health clinics in the
northeast, south and central regions of Colombia.
Inclusion Criteria Patients included in this study met
the following criteria: a) positive parasitologic diagnosis
of leishmaniasis, b) no previous treatment for this para-
sitic infection, c) laboratory exams including renal, hep-
atic and hematologic testing and d) voluntary agreement
to participate in the study.
Exclusion criteria Patients with the following character-
istics were excluded: a) chronic concomitant diseases, b)
lesions compromising the mucosa, c) presence of 10 or
more cutaneous lesions with a negative Montenegro test
or d) cutaneous lesions located less than 2 cm from the
nasal or oral mucosa, eyes or near the anal or urogenital
orifices.
Interventions Thermotherapy (ThermomedW, Thermo-
surgery Inc. Phoenix-USA). Following the aseptic prepar-
ation of the lesions and local anesthesia with 2%
xylocaine, we applied a single session of thermotherapy
to the center, active borders and peripheral area of the
lesions. Each thermal application was at 50°C and lasted
for 30 seconds; the number of applications depended on
the size of the lesion. After the thermotherapy session
and over the next 10 days, an antibiotic ointment (fusidic
acid) was applied over the lesions, which were then cov-
ered with sterile gauze to prevent secondary infections.
Meglumine antimoniate (GlucantimeW, Aventis, Paris,
France) was administered intramuscularly under medical
supervision at a dose of 20 mg Sb5/kg/day for 20 days.
All patients of both groups remained within the military
unit for the duration of the treatment.
Data collection and samples
After providing writing informed consent, all patients
were given a medical chart with pertinent demographic
information, lesion data and a review of inclusion/exclu-
sion criteria. We subsequently photographed each lesion.
Histologic samples were taken from all patients to con-
firm the diagnosis and to identify the type of Leishmania
using PCR-RFLP, according to published guidelines [35].
Clinical samples were taken from all subjects for
the parasitological confirmation of leishmaniasis by
direct microscopic examination, lesion aspirate samples
were taken from each of the patients and were processed
as explained in other publications [35,36]. In brief, the
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bated at 26°C, and from the fourth day on they were
observed weekly for one month, in the inverted micro-
scope in search of promastigotes. The media cultures
were labeled with the code of each participant and were
stored on independent racks to avoid mixing. Each week
positive cultures were mass cultured in 50 ml glass
bottles with NNN modified medium, one part was frozen
in liquid nitrogen and is now stored in the PECET
Criobank, and the other was used for species identifica-
tion; for the DNA extraction, Promastigotes cultures
were centrifuged and washed three times for 5 min at
1000 g in PBS pH 7.6. Parasites were then re-suspended
in 200 μl of lysis buffer (10 mM Tris–HCl, pH 8,5 mM
EDTA, 0.5% SDS, 200 mM NaCl, 100 μg/ml proteinase K)
for 90 min at 65°C with moderate agitation. DNA was
precipitated by adding two volumes of absolute ethanol
to the lysate and the solution was mixed by inversion, and
centrifuged for 15 min at 10,000 g. To recover the DNA,
the supernatant was discarded and the pellet was dried for
15 min at 65°C and then re-suspended in 200 μl of water
or TE. Then for the PCR amplification of the Cpb gene.
Due to the partial degree of variability of the Cpb
sequence between the Viannia and Leishmania
subgenus, Cpb-specific primers were designed using the
primer3plus software (www.bioinformatics.nl/cgibin/pri-
mer3plus/primer3plus.cg). A region of the Cpb gene in
L. (V) panamensis, L. (V) braziliensis and L. (V) guyanensis
were amplified with the primers FwNTerBra (5´-
ATGACGGTGCCGAGGGTCCT-3´) and RvCTerBra (5’-
CTACTTGAACGTGCAGAT-3’); while primers FwRGPS
(5’-ATGGCGACGTCGAGGGCC-3’) and RvRGPS (5’-
CAGGTGTTCATGATCGAGCCC-3’) were used for L. (L)
mexicana and L. (L) infantum; To amplify the Cpb region of
L. (L) amazonensis the primers FwRPAMZ (5’-GGATC
CATACACGTGGGCACGCCG-3’) and RvRPAMZ (5’-
AAGCTTCTACGTGTAGTGACAGGT-3’) were used.
These last pair of primers also amplify for L. (L)Mexicana.
After each PCR round, 5 μl of the product were sepa-
rated in a 1% agarose gel and stained with 0,5 μg/ml of
ethidium bromide. DNA products were visualized using
a Chemidoc image analyzer system (Bio-Rad, Hercules,
California, USA).
In order to identify the Leishmania species by RFLP,
the NEBcutter V2.0 programme (New England Biolab,
Ipswich, Massachusetts, USA) was used to generate
species-specific restriction sites. To differentiate L. (V)
panamensis from L. (V) braziliensis, 10 μl of the amplifi-
cation product was digested with KpnI (Promega), the
mix was incubated for 6 h at 37°C. To differentiate L. (V)
panamensis from L. (V) guyanensis, 10 μl of the amplifi-
cation product was digested with NsiI (New England
Biolab), this mix was incubated for 16 h at 37°C. To dif-
ferentiate L. (L) mexicana from L. (L) amazonensis, 10 μlof the amplification product was digested, with NarI
(New England Biolab), and the mix was incubated for 6 h
at 37°C. To differentiate L. (L) mexicana from L. (L) infan-
tum, 10 μl of the amplification product was digested with
KpnI (Promega). After digestion, products were separated
in 1% or 2% agarose gel using the same conditions
described above for visualizing the PCR-Cpb amplification
products[37,38].Assignment to the treatment group Subjects were
assigned randomly to treatment groups using a generated
list in blocks of eight (EpiInfo 3.1). Only the clinical
coordinator of the study had access to the list and was
in charge of allocating treatments.Follow-up and outcomes Subjects receiving Meglu-
mine antimoniate were evaluated at the beginning and
end of treatment, at 6 weeks and at 3 and 6 months after
completing the treatment. Subjects receiving thermo-
therapy were evaluated on the same day they started the
treatment, at days 10 and 20, at 6 weeks and at 3 and
6 months after the application of heat, although thermo-
therapy was applied in an only session the followup of
the healing process of the lesions was carried out three
weeks after application, coinciding with the visit of final
treatment of the group that received Meglumine anti-
moniate. All patients underwent renal, hepatic, pancre-
atic and hematologic blood function tests before, during
and after the completion of treatment. The assessment
of side effects was done according to the Common Ter-
minology Criteria for Adverse Events v.3 (CTCAE) [39].
The treatment response was evaluated clinically. For
each lesion, the following definitions were used:Initial healing Complete reepithelialization of all ulcers
and complete loss of induration up to three months after
the end of treatment.Definitive healing Initial healing criteria without any re-
currence six months after the completion of treatment.Failure Increase in size of a lesion of more than 50% at
the end of treatment or an absence of clinical response
at 6 weeks (lesion size reduction less than 50% compared
to the evaluation at the end of treatment), signs of lesion
activity 3 months after the completion of treatment or
recurrence or presence of mucosal leishmaniasis at any
time 6 months after the end of treatment.Recurrence Lesion reactivation in the original site after
cicatrization.
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different from the original lesions after the patient was
considered healed and after returning to endemic areas.
In all subjects that had a treatment failure, Meglu-
mine antimoniate was provided as rescue therapy at
a dose of 20 mg Sb5/kg/day for 20 days, according to
the Colombian Ministry of Health guidelines [40].
Sample size calculation The sample size was calculated
assuming a thermotherapy efficacy of 78%, Meglumine
antimoniate efficacy of 90%, confidence interval (CI) of
95% and power of 80% (non-inferiority trial). To this
sample size number, we added 20% to account for possible
loss of subjects to follow-up. The total sample size was 144
subjects per group for a total of 288 participants.
Statistical analysis Data entry and data analysis were
performed using ACCESS and SPSS v.15, respectively.
The baseline characteristics of volunteers were categor-
ized and analyzed by treatment group. The treatment effi-
cacy was calculated by intention-to-treat and by protocol.
The relative risk was calculated using 2x2 tables. For hy-
pothesis tests in dichotomic variables, we used the Fisher's
Test or X2 test. The student's t-test or the “U of
Mann–Whitney” test was used to analyze continuous
data. Potential confounding factors and interactions were
controlled with analysis stratified by parasite species, num-
ber, location, type of lesions and geographic area where the
infection occurred. Statistical survival analysis was per-
formed using the Kaplan-Meier method and the log rank
test to compare the healing time between both
groups. A p value of <0.05 was considered as stasti-
cally significant and CI of 95% was used for data analysis.
Results
We included 292 subjects in the study and randomly
assigned 149 to receive thermotherapy and 143 to re-
ceive Meglumine antimoniate. In the thermotherapy
group, two subjects did not want to participate (1%), 13
(9%) did not complete the six month follow-up and a
total of 134 (90%) completed the study. In the Meglu-
mine antimoniate group, 18 (13%) did not complete the
six month follow-up, 2 (1%) withdrew from the Army
before completing the study, 2 (1%) died in combat and
121 (85%) completed the study, as shown in Figure 1.
Recurrences
Recurrence was reported in 6 (4.1%) and 4 (3%) patients
for the thermotherapy and Meglumine antimoniate
groups, respectively. All of these patients received Meglu-
mine antimoniate as a rescue treatment, and only one pa-
tient, who was assigned to the Meglumine antimoniate
group, required a third treatment with amphotericine B.All recurrences occurred within 3 months of treatment
completion.
Baseline analysis
As shown in Table 1, both groups had similar demo-
graphic, clinical and parasitologic characteristics.
Therapeutic response
Initial healing Three months after the end of treatment,
64% (95% IC 56–72) of the thermotherapy group and
78% (95% IC 71–85) of the Meglumine antimoniate
group were healed.
Definitive healing A total of 7 patients (4.8%) from the
thermotherapy group and 7 (5%) from the Meglumine
antimoniate group did not complete follow-up with the
3- and 6-month evaluations. By protocol, 64% (95% IC
55–73) of patients in the thermotherapy group and 85%
(95% IC 64–80) of patients in the Meglumine antimoni-
ate group showed definitive healing. By intention-to-
treat, the definitive healing rate in the thermotherapy
group was 58.5% (95% IC 49–66) and 72% (95% IC 78–
92) in the Meglumine antimoniate group, as shown on
Table 2. The efficacy analysis between both treatments
showed a statistically significant difference, for the ana-
lysis by protocol the Meglumine antimoniate is 0.33
times more effective than thermotherapy (RR 1.33 (IC
95% 1.15 – 1.54) p <0.001), when analysis was carried
out by intention to treat, the superiority of the Meglu-
mine antimoniate maintained, being 0.25 more effect-
ive than thermotherapy (RR 1.25 (IC 95% 1.05 – 1.48)
p <0.001).
Group analysis
We identified Leishmania species as agents of infection
in 167 patients. In the group treated with Meglumine
antimoniate, 32 patients (38%) had lesions caused by
L. (V) panamensis and 52 (62%) by L. (V) brazililensis. In
the thermotherapy group, 24 patients (29%) had lesions
caused by L. (V) panamensis and 59 (71%) by L. (V)
brazililensis.
The healing response in the Meglumine antimoniate
group, among patients with L. (V) panamensis and L. (V)
braziliensis, was of 72% and 65%, respectively. In the
thermotherapy group, the healing response was 58% for
L. (V) panamensis and 53% for L. (V) braziliensis. There
was no association found between the treatment (Meglu-
mine antimoniate, p = 0.5, and thermotherapy, p = 0.6)
and the Leishmania species identified.
There was also no association between treatment and
other variables such as number, location and lesion type
or with the geographical area of Colombia where the in-
fection occurred (Table 3).
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Table 4 shows the systemic and local side effects found
in this study. Frequency and severity of side effects were
greater in the Meglumine antimoniate group. These side
effects occurred during and after treatment. These side
effects included fever, myalgia, arthralgia and headache.
In the group treated with thermotherapy, we found an
association with local pain, especially four days after ini-
tiating treatment (p =<0.001).
In all laboratory analysis conducted during and at the
end of treatment with Meglumine antimoniate, there
were alterations in renal, hepatic, pancreatic and
hematologic tests. There was an association with
increased amylase levels (p< 0.005), which reached
grade 3 in some cases [39].
Severe side effects
Three patients experienced serious adverse effects, none
of which were related to medications (2 died in combat
and 1 was wounded by a knife). These three patients
were part of the Meglumine antimoniate group.
Survival analysis
The Meglumine antimoniate group experienced signifi-
cantly fewer failures to treatment (15%) compared to the
thermotherapy group (36%) (log rank = 9.6, p =<0.001).
Discussion
This study followed procedures delineated by the GCP. The
sample size was adequate for the study. The follow-up rate
was 88% at six months after treatment, which was higher
than estimated when calculating the sample size.
In the Meglumine antimoniate group, treatment efficacy
by protocol and intention-to-treat were 85 and 72%, re-
spectively. These results demonstrate a decrease in the
rate of efficacy for this age group, which was reported as
93% during the 1990s [41-43]. This decrease in the efficacy
of antimonials could be related, among other factors, to
the administration of incomplete doses as a consequence
of adherence problems, unavailability of a complete dose
to all patients, black market of medications in rural areas
and evidence that men also play a role in the transmission
of American cutaneous leishmaniasis [29]. There was no
statistically significant difference in terms of treatment effi-
cacy with leishmania species.
Thermotherapy had an efficacy of 64 and 58% per
protocol and intention-to-treat, respectively; these results
are comparable to the findings reported by a study in
Kabul, Afghanistan, (CL due to L. (L) tropica) in which
the efficacy per protocol was 69% [44]. In other study
made with patients from other Asian countries (Irán and
Kuwait), following the same conditions of application of
local heat and where the isolated specie was L. (L) major,the intent efficacy of thermotherapy to treat was 48%,
two months after treatment ends [45].
With regard to efficiency, we found that Meglumine anti-
moniate is statistically superior to thermotherapy for the
treatment of CL in Colombia (p< 0.001), but we also found
that Meglumine antimoniate has been associated with se-
vere side effects in the musculoskeletal system (myalgia and
arthralgia), fever, headaches [4] and toxicity in organs such
as the kidney, the pancreas and the hematologic and cardio-
vascular systems. These effects are not associated with ther-
motherapy, which only causes local pain four days after the
initiation of treatment.
Systemic treatment with pentavalent antimonials for
cutaneous leishmaniasis caused by L. (V) panamensis and
L. (V) braziliensis was recommended by the WHO in
1990 under the assumption that such treatment prevents
the development of mucosal lesions[46]. However, subse-
quent studies conducted in Peru demonstrated that mu-
cosal lesions may appear despite the use of these
therapeutic schemes. In the case of Colombia, where the
predominant parasite species are L. (V) braziliensis and
L. (V) panamensis, the need for all patients to receive
systemic treatment of 20 mg Sb5/kg/day for 20 days is
even more controversial, especially because the incidence
of mucosal leishmaniasis is less than 0.5% although it is
estimated that, in rural areas far from health centers,
only 10% of the population with CL receives complete
treatment with antimonials [28-30]. Unpublished data
(Dirección de Sanidad del Ejército (DISAN) and Pro-
grama de Estudio y Control de Enfermedades Tropicales
(PECET)) documented 12 fatalities related to the use of
this therapy, which is unacceptable for a form of the dis-
ease that is not fatal.
Thermotherapy has been evaluated in several Ameri-
can and Old World countries with efficacy rates of more
than 70%. In Colombia, only one report of thermother-
apy used to treat CL was made in an epidemic area of
L. (V) guyanensis. In this region, thermotherapy had an
efficacy of 100 and 19% by protocol and intention-to-
treat, respectively, although the lack of follow-up in
many patients (81%) decreased the efficacy of the study
and limited the interpretation of results [47].
The facts mentioned previously led us to ponder the
convenience of using local treatments (thermotherapy,
paromomicine, cryotherapy, intra-lesion pentavalent an-
timony) in combination with patient education on how
to detect early signs and symptoms of mucosal complica-
tions so they can be promptly reported to the physician
and addressed with systemic treatment.
The results of the present study show that thermo-
therapy could be considered a valid alternative treatment
due to its efficacy (>60%) and safety as well as because
it requires a single session and does not require labora-
tory monitoring.
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(ThermoMed) is very expensive and difficult to access in
endemic countries due to its cost, the expenses related
to conventional treatment overweigh the costs of
Thermomed.
With the goal of increasing its efficacy, we propose a sub-
sequent clinical trial to evaluate new schemes of application
of local treatment with thermotherapy; for example,
patients may undergo 2–3 sessions or a combination of
local treatments with a low systemic dose.
Conclusions
Although the efficacy rate of Meglumine antimoniate
was greater than that of thermotherapy for the treatment
of cutaneous leishmaniasis, the side effects were also
greater. Those factors, added to the increased costs, the
treatment adherence problems and the progressive lack
of therapeutic response, make us consider thermotherapy
as a first line treatment for cutaneous leishmaniasis.
The thermotherapy is also a valid alternative in
patients with renal, hepatic and cardiac illness who can-
not receive systemic therapy. It is important to mention
that thermotherapy should not be applied near mucosal
areas.
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